Design Therapeutics (DSGN) Depreciation & Amortization (CF) (2020 - 2026)

Design Therapeutics has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $157000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $157000.0, down 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $620000.0 (up 1.31% YoY), and the FY2025 annual result was $622000.0, up 4.36% from the prior year.
• Depreciation & Amortization (CF) came in at $157000.0 for Q1 2026 at Design Therapeutics, up from $156000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $159000.0 in Q1 2025 to a low of $82000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $143000.0 (2024), against an average of $136352.9.
• Across the five-year window, Depreciation & Amortization (CF) surged 1950.0% in 2022 and slipped 1.26% in 2026, its largest moves.
• Design Therapeutics' Depreciation & Amortization (CF) stood at $124000.0 in 2022, then advanced by 11.29% to $138000.0 in 2023, then increased by 7.97% to $149000.0 in 2024, then gained by 4.7% to $156000.0 in 2025, then rose by 0.64% to $157000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $157000.0 (Q1 2026), $156000.0 (Q4 2025), and $155000.0 (Q3 2025), per Business Quant data.